Tandem Diabetes Care (NSDQ:TNDM) won a medical device license from Health Canada last week for its t:slim X2 insulin pump.
The device integrates directly with Dexcom‘s (NSDQ:DXCM) G5 continuous glucose monitor and is the only system of its kind approved in Canada, according to the San Diego, Calif.-based company.
Tandem said it plans to launch the t:slim X2 insulin pump on a province-by-province basis throughout the fourth quarter of this year, pending product registration with local health programs.
The system is up to 38% smaller than other insulin pumps, Tandem touted, and can hold up to 300 units of insulin.
“People with diabetes in Canada have been asking for our simple-to-use pump technology since the inception of Tandem and I am thrilled that we are now able to offer a fresh, new choice in insulin pump therapy,” president & CEO Kim Blickenstaff said in prepared remarks. “This launch is especially important since insulin pump options in Canada have become increasingly limited in recent years, and this approval will allow us to bring the benefits of our technology to more people with diabetes.”
In August, Tandem launched its t:slim X2 insulin pump with Basal-IQ technology in the U.S. The company’s latest device includes a predictive low glucose suspend feature designed to reduce the frequency and duration of hypoglycemia.
